Quinazoline derivatives, process for their preparation, pharmaceutical preparations and their preparation, and n-(2-aminobenzyl)-glycine derivatives.
Abstract
Neue Chinazolinderivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate und deren Herstellung sowie N-(2-Aminobenzyl)- glycinderivate. Die vorliegende Erfindung betrifft neue tricyclische Verbindungen, nämlich Imidazo-chinazoline der Formel worin R1 und R2 Wasserstoff, nieder-Alkyl, Hydroxy, nieder-Alkoxy, Hydroxy-nieder- alkyl, nieder-Alkoxy-nieder-alkyl, Halogen, Phenyl, Phenoxy, Amino, nieder-Alkylamino oder di-nieder- Alkylamino, und R' und R2 an benachbarten Kohlenstoffatomen auch gemeinsam Methylendioxy; R3 Wasserstoff, nieder-Alkyl oder Phenyl; und R4 nieder-Alkyl, Hydroxy-nieder- alkyl, nieder-Alkoxy- nieder-alkyl, Aryl-nieder- alkyl oder Aryl bedeuten, <br /> deren Tautomere und Salze solcher Verbindungen. Diese Verbindungen und Salze hemmen die Aggregation der Blutplättchen und haben positive inotrope Wirkund ohne wesentliche Tachycardie. Sie können in an sich bekannter Weise hergestellt werden, u.a. ausgehend von neuen N-(2-Aminobenzyl)- glycinderivaten.

Term
Term ended
Projected expiry passed 21 July 1998, 28.2 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
1 sheet
Sheet 1
Every citation, both ways
| Document | Relation | Office | Category | Cited during |
|---|---|---|---|---|
| DE1445906A1 | Cites | Germany | A | Search report |
| DE2305575A1 | Cites | Germany | A | Search report |
49 members in 31 offices
Priority claims10
| Document | Office | Kind | Date |
|---|---|---|---|
| 77829 | Luxembourg | A | |
| 77829 | Luxembourg | A | |
| 77829 | Luxembourg | – | |
| 577678 | Switzerland | A | |
| 577678 | Switzerland | A | |
| 577678 | Switzerland | – | |
| 577678 | – | – | – |
| 77829 | – | – | – |
| CH19780005776 | – | – | – |
| LU19770077829 | – | – | – |
Members49
| Document | Office | Kind | |
|---|---|---|---|
| PT68342A | Portugal | A | |
| IE781478L | Ireland | L | |
| DK328978A | Denmark | A | |
| FI782248A | Finland | A | |
| FI782248A7 | Finland | A7 | |
| NO782541L | Norway | L | |
| SE7808111L | Sweden | L | |
| NL7807507A | Netherlands (Kingdom of the) | A | |
| GB2001638A | United Kingdom | A | |
| DE2832138A1 | Germany | A1 | |
| EP0000718A2 | European Patent Office (EPO) | A2 | |
| FR2398748A1 | France | A1 | |
| MC1199A1 | Monaco | A1 | |
| JPS5441894A | Japan | A | |
| BR7804763A | Brazil | A | |
| EP0000718A3This record | European Patent Office (EPO) | A3 | |
| ZA784080B | South Africa | B | |
| ES471981A1 | Spain | A1 | |
| ES476955A1 | Spain | A1 | |
| AU3812778A | Australia | A | |
| AR218500A1 | Argentina | A1 | |
| ATA419380A | Austria | A | |
| ATA535178A | Austria | A | |
| CA1094555A | Canada | A | |
| CS203014B2 | Czechoslovakia (until 1993) | B2 | |
| NZ187921A | New Zealand | A | |
| US4256748A | United States of America | A | |
| CU21030A | Cuba | A | |
| AT363479B | Austria | B | |
| AT363481B | Austria | B | |
| FR2398748B1 | France | B1 | |
| PH14642A | Philippines | A | |
| HU177643B | Hungary | B | |
| IL55183A | Israel | A | |
| DK144128B | Denmark | B | |
| AU519688B2 | Australia | B2 | |
| GB2001638B | United Kingdom | B | |
| EP0000718B1 | European Patent Office (EPO) | B1 | |
| DE2861688D1 | Germany | D1 | |
| DK144128C | Denmark | C | |
| YU177578A | Yugoslavia, later Serbia and Montenegro (until 2006) | A | |
| FI63409B | Finland | B | |
| FI63409C | Finland | C | |
| GR72968B | Greece | B | |
| IE47280B1 | Ireland | B1 | |
| NO150800B | Norway | B | |
| NO150800C | Norway | C | |
| IT1097337B | Italy | B | |
| MY8500249A | Malaysia | A |
29 legal events, as 3 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Se: european patent has lapsedLapsedEUG | EUG | EP | |
| Notification of lapseLapsedST | ST | FR | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Patent ceasedCeasedPL | PL | CH | |
| Nl: lapsed or anulled due to non-payment of the annual feeLapsedNLV4 | NLV4 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Be: lapsedLapsedBERE | BERE | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Corresponds to:REF | REF | EP | |
| Designated contracting statesAK | AK | EP | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Search report despatchedORIGINAL CODE: 0009013PUAL | PUAL | EP | |
| Designated contracting statesAK | AK | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 0000718
- Publication, DOCDB
- 0000718
- Publication, EPODOC
- EP0000718
- Application
- 78100471
- Application, DOCDB
- 78100471
- Application, EPODOC
- EP19780100471
Titles3
- English
- Quinazoline derivatives, process for their preparation, pharmaceutical preparations and their preparation, and N-(2-aminobenzyl)-glycine derivatives.
- French
- Dérivés de la quinazoline, procédé pour leur préparation, préparations pharmaceutiques et leur préparation et dérivés de la N-(2-amino-benzyl)-glycine.
- German
- Neue Chinazolinderivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate und deren Herstellung sowie N-(2-Aminobenzyl)-glycinderivate
Classification
- CPC, 3
- C07D487/04
- A61P7/02
- A61P9/04
- IPC, 5
- A61K31 505
- A61P7 02
- A61P9 04
- C07D233 68
- C07D487 04
Designated states1
- Contracting states, 1
- Sweden